Novo Nordisk A/S has disclosed its latest share repurchase activity under its ongoing DKK 15 billion buyback programme, revealing that 890,000 B shares were purchased across four trading sessions between 3 November and 6 November 2026. The Danish pharmaceutical giant, listed on Nasdaq Copenhagen as Novo-B and on the New York Stock Exchange as NVO, has now accumulated repurchases of 27,845,000 B shares worth DKK 8,008,013,722 under the sub-programme initiated on 6 May 2026. Investors tracking capital return activity at one of Europe's largest healthcare companies will note the programme remains active through to 1 February 2027.

Key Points

  • Novo Nordisk A/S Class B (0QIU), listed on Nasdaq Copenhagen (Novo-B) and NYSE (NVO)
  • 890,000 B shares repurchased between 3 November and 6 November 2026 across four daily transactions
  • Accumulated programme spend stands at DKK 8,008,013,722 on 27,845,000 shares; overall buyback target is DKK 15 billion over 12 months from 4 February 2026
  • Investors should watch the pace of remaining repurchases, with up to DKK 11.2 billion authorised under the sub-programme running to 1 February 2027

Daily Buyback Volumes and Prices: 3–6 November 2026 Transactions

The announcement details four individual daily purchases. On 3 November 2026, Novo Nordisk bought 230,000 B shares at an average price of DKK 269.17, for a transaction value of DKK 61,908,086. The following day, 220,000 shares were acquired at DKK 281.05, totalling DKK 61,830,237. On 5 November, a further 220,000 shares were purchased at DKK 276.98, amounting to DKK 60,935,927, and on 6 November, 220,000 shares were bought at DKK 268.07, equating to DKK 58,974,660. These transactions bring the accumulated total under this sub-programme to DKK 8,008,013,722.

Novo Nordisk's Total Treasury Share Position and Overall 2026 Programme Progress

Following these transactions, Novo Nordisk holds 56,644,876 B shares as treasury shares, each with a nominal value of DKK 0.10, representing 1.3% of the company's total share capital of 4,465,000,000 A and B shares combined. Since the broader 12-month buyback programme commenced on 4 February 2026, Novo Nordisk has repurchased a cumulative 42,604,179 B shares at an average price of DKK 277.16 per share, for a total transaction value of DKK 11,808,013,711 as of 6 November 2026.

Regulatory Framework Governing Novo Nordisk's Safe Harbour Repurchase Activity

The buyback is conducted in accordance with Article 5 of the EU Market Abuse Regulation (No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052, commonly referred to as the Safe Harbour Rules. The sub-programme initiated on 6 May 2026 authorises repurchases of up to DKK 11,200,000,010.45 in B shares through to 1 February 2027. Full transaction-level details for each individual purchase are published on novonordisk.com, as required under the regulatory framework. With over 67,000 employees globally, Novo Nordisk develops treatments serving millions of patients worldwide.